Insider Buying: CSL (ASX:CSL) Insider Acquires A$32,432.98 in Stock

CSL Limited (ASX:CSL) insider Alison Watkins acquired 214 shares of the stock in a transaction dated Tuesday, February 17th. The stock was bought at an average cost of A$151.56 per share, with a total value of A$32,432.98.

CSL Price Performance

The firm has a market cap of $77.43 billion, a price-to-earnings ratio of 28.02, a P/E/G ratio of 1.29 and a beta of 0.32. The company has a quick ratio of 1.68, a current ratio of 1.86 and a debt-to-equity ratio of 64.46.

CSL Announces Dividend

The business also recently disclosed a Interim dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Wednesday, April 8th will be paid a dividend of $1.837 per share. The ex-dividend date is Monday, March 9th. This represents a yield of 121.0%. CSL’s dividend payout ratio (DPR) is 50.38%.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.